The impact of Angiotensin II Type 1 Receptor antibodies on morbidity and mortality in Heart Mate II supported recipients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F16%3A00060238" target="_blank" >RIV/00023001:_____/16:00060238 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/16:43911470

Výsledek na webu

<a href="http://biomed.papers.upol.cz/artkey/bio-201604-0010_the_impact_of_angiotensin_ii_type_1_receptor_antibodies_on_morbidity_and_mortality_in_heart_mate_ii_supported_r.php" target="_blank" >http://biomed.papers.upol.cz/artkey/bio-201604-0010_the_impact_of_angiotensin_ii_type_1_receptor_antibodies_on_morbidity_and_mortality_in_heart_mate_ii_supported_r.php</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2016.025" target="_blank" >10.5507/bp.2016.025</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The impact of Angiotensin II Type 1 Receptor antibodies on morbidity and mortality in Heart Mate II supported recipients

Popis výsledku v původním jazyce

Aims. One of the proposed limitations of left ventricular assist device (LVAD) therapy is high degree of sensitization. Apart from human leukocyte antigen (HLA), antibodies against Angiotensin II Type 1 Receptor (AT1R) have been associated with adverse outcomes. The purpose of this study was to compare complications and survival of anti-AT1R positive versus negative Heart Mate II (HMII) recipients. Methods. Altogether 96 patients received HMII at our institution between 2008 and 2012. These were stratified into three groups: antibody positive before implantation (AT1R+), antibody conversion during support (AT1R-/+) and patients who remained antibody negative (AT1R-). Survival, major on-device adverse events and post-transplant rejections were assessed with Kaplan-Meier and log-rank tests. Results. Two year on-device and overall survival was 78 +/- 12% and 75 +/- 10% in AT1R-, 60 +/- 23% and 60 +/- 15% in AT1R+ and 92 +/- 6% and 87 +/- 5% in AT1R-/+ group (P = 0.409, P = 0.185). Freedom from major adverse event at two years for AT1R-, AT1R+ and AT1R-/+ was 49 +/- 14%, 53 +/- 16% and 41 +/- 11% (P = 0.875). Freedom from rejection was 63 +/- 17% in patients who were both anti-AT1R and HLA negative and 65 +/- 13% in those who were antibody positive (P = 0.788). Conclusion. Patients who were anti-AT1R antibody positive had similar on-device survival and rate of complications in comparison to those who were antibody negative. In transplanted patients, there were no differences in the overall survival and rejection between the groups.

Název v anglickém jazyce

The impact of Angiotensin II Type 1 Receptor antibodies on morbidity and mortality in Heart Mate II supported recipients

Popis výsledku anglicky

Aims. One of the proposed limitations of left ventricular assist device (LVAD) therapy is high degree of sensitization. Apart from human leukocyte antigen (HLA), antibodies against Angiotensin II Type 1 Receptor (AT1R) have been associated with adverse outcomes. The purpose of this study was to compare complications and survival of anti-AT1R positive versus negative Heart Mate II (HMII) recipients. Methods. Altogether 96 patients received HMII at our institution between 2008 and 2012. These were stratified into three groups: antibody positive before implantation (AT1R+), antibody conversion during support (AT1R-/+) and patients who remained antibody negative (AT1R-). Survival, major on-device adverse events and post-transplant rejections were assessed with Kaplan-Meier and log-rank tests. Results. Two year on-device and overall survival was 78 +/- 12% and 75 +/- 10% in AT1R-, 60 +/- 23% and 60 +/- 15% in AT1R+ and 92 +/- 6% and 87 +/- 5% in AT1R-/+ group (P = 0.409, P = 0.185). Freedom from major adverse event at two years for AT1R-, AT1R+ and AT1R-/+ was 49 +/- 14%, 53 +/- 16% and 41 +/- 11% (P = 0.875). Freedom from rejection was 63 +/- 17% in patients who were both anti-AT1R and HLA negative and 65 +/- 13% in those who were antibody positive (P = 0.788). Conclusion. Patients who were anti-AT1R antibody positive had similar on-device survival and rate of complications in comparison to those who were antibody negative. In transplanted patients, there were no differences in the overall survival and rejection between the groups.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical papers

ISSN

1213-8118

e-ISSN

—

Svazek periodika

160

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

518-523

Kód UT WoS článku

000392810500010

EID výsledku v databázi Scopus

—